fda glp-1 warning news september 2025 Targets and Peptide Compounding, Advertising and 'Research Use Only' Labeling Compounded" GLP-1 drugs | Health

Why some fractures fail to heal Not every fracture follows the textbook healing timeline

NICE guidance (NG100) recommends disease-modifying antirheumatic drugs (DMARDs) as standard care, with methotrexate as first-line therapy

Why is the GLP-1 Slimming & Health Boost Drops considered the top choice

Medicare Part D coverage expansion: The proposed CMS rule allowing Medicare Part D plans to cover anti-obesity medications would make 31 million Medicare beneficiaries with obesity eligible for semaglutide and tirzepatide, representing a USD 55.8 billion annual drug spend potential at 15% initial penetration

But the study also finds that, at least in the short run, they do not reduce overall health care spending